There are currently 874 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
NCT05373017
Recruiting
This study will evaluate the usefulness of the Emergency General Surgery (EGS) Delirium Recovery Model. It is hypothesized that the cognitive, physical and psychological recovery of older EGS delirium survivors will be improved through the use of the EGS Delirium Recovery Model. Participants can expect to be on the study for 18 months.
Gender:
All
Ages:
65 years and above
Trial Updated:
05/10/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Delirium
Register for Updates
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
NCT06302348
Recruiting
The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.
Gender:
All
Ages:
12 years and below
Trial Updated:
05/10/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Phenylketonuria
Register for Updates
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678
Recruiting
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enroll... Read More
Gender:
All
Ages:
All
Trial Updated:
05/10/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Phenylketonuria (PKU)
Register for Updates
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
All
Ages:
All
Trial Updated:
05/10/2024
Locations: Indiana University, IU Health Methodist Hospital, Indianapolis, Indiana
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Register for Updates
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
NCT06173570
Recruiting
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded ac... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/09/2024
Locations: Research Site, Indianapolis, Indiana
Conditions: Dyslipidemia
Register for Updates
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
NCT04068753
Recruiting
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Recurrent Cervix Cancer, Progressive Cervix Cancer
Register for Updates
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935
Recruiting
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
05/09/2024
Locations: Indiana University (IU) Health Physicians - IU Health Neuroscience Center, Indianapolis, Indiana
Conditions: Eosinophilic Esophagitis
Register for Updates
Gastroschisis Outcomes of Delivery (GOOD) Study
NCT02774746
Recruiting
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks o... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Riley Children's Hospital, Indianapolis, Indiana
Conditions: Gastroschisis
Register for Updates
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
NCT05203510
Recruiting
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Indiana University Health North Hospital, Indianapolis, Indiana
Conditions: Pulmonary Arterial Hypertension
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
Female
Ages:
Between 15 years and 55 years
Trial Updated:
05/08/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT04662580
Recruiting
This is a phase 1 study to assess the safety and tolerability of ARX517 in adult subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Prostate Cancer
Register for Updates